March 11, 2026 4:54pm

Econs impaled share pricing as markets reacted to the CPI report, with stock market falling and Treasury yields higher

The report showed inflation broadly stable, prices rose modestly for shelter and services while several goods categories, the CPI showed receding costs in goods most impacted by tariffs, and rising prices for key services components such as medical care, airline fares, and lodging.

News: 2 (below)

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

News: REGENXBIO (RGNX -$0.52 or -5.26% to $9.38) new positive interim data from the P1/2 AFFINITY DUCHENNE trial of RGX-202, a gene therapy for Duchenne muscular dystrophy.  The data demonstrates continued positive impact on function, stable cardiac health, and a favorable safety profile, highlighting the potential of RGX-202 to be a differentiated gene therapy option for Duchenne.

Solid Biosciences (SLDB -$0.47 or -5.68% to $7.72) reported updated positive interim data from the ongoing P1/2 INSPIRE DUCHENNE clinical trial of SGT-003. The new data, including additional muscle biopsy, serum biomarker, cardiac function, and safety analyses, add to a growing dataset that suggests the potential of the biological activity of SGT-003 microdystrophin therapy.

 

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Pre-opening: Econs plus moving parts … https://www.regmedinvestors.com/articles/14344   

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt, barely fulfills the need of a PPM raise … https://www.regmedinvestors.com/articles/13812

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Wednesday: The Dow closed DOWN -289.24 points or -0.61%, the S&P closed DOWN -5.68 points or -0.08% while the Nasdaq closed UP +19.031 points or +0.08%

  • Theme of the session: oil pricing

Tuesday’s (my) 40-company covered sector’s advance/decline line opened negative with 9 incliners, 29 decliners and 2 flats, ending with a negative close of 12 incliners, 26 decliners and 2 flats

  • The C&GT sector is wrestling with that infection of short-termitis caused by econs and oil pricing

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • The consumer price index increased a seasonally adjusted 0.3% for the month, putting the 12-month inflation rate at 2.4%.
  • The core CPI posted a 0.2% monthly reading and 2.5% annual rate, compared with forecasts for 0.2% and 2.5%. All of the figures were in line with Wall Street estimates.
  • Rent rose just 0.1%, the smallest monthly increase since January 2021.
  • Food prices accelerated 0.4% for the month and were up 3.1% from a year ago. Egg prices fell 3.8%, putting the annual drop at 42.1%.

The CBOE Fear (VIX) index, Wednesday closed at 24.31, after Tuesday’s 25.46, Monday’s 25.54, after Friday’s 20.49, Thursday’s 23.64 and last Wednesday’s 21.15,

Metrics: Tuesday …

  • The RUT was down -5.18 points or -0.20%,
  • The XLV was down -0.30 points or -0.20%,
  • The NBI was down -39.19 points or -0.66%;
  • The XBI was down -1.04 points or -0.82%
  • The IWM was down -0.50 or -0.20%;
  • The IBB was down -1.40 points or -0.81%,
  • The VIX was down -0.62 points or -2.48% at to 24.31

 

Q1/26 – March – 2 positive and 5 negative closes

  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Wednesday Closing UP (12 of 12) 

  • BioNTech (BNTX +$6.95 after Tuesday’s -$18.27),
  • AxoGen (AXGN +$1.60 after Tuesday’s +$1.41),
  • Moderna (MRNA +$0.99 after Tuesday’s -$0.76 after Monday’s +$3.22),
  • IQAI Holdings (IQV +$0.69 after Tuesday’s -$7.64 after Monday’s +$4.06),
  • BioLife Solutions (BLFS +$0.34 after Tuesday’s -$1.23),
  • Wave Life Sciences (WVE +$0.334 after Tuesday’s +$0.46),
  • Entrada Therapeutics (TRDA +$0.30 after Tuesday’s +$0.50),
  • Dyne Therapeutics (DYN +$0.21 after Tuesday’s +$2.09 after Monday’s +$2.83),
  • Capricor Therapeutics (CAPR +$0.17 after Tuesday’s +$2.77 after Monday’s +$2.73),
  • Lenz Therapeutics (LENZ +$0.08),
  • Brainstorm Cell Therapeutics (BCLI +$0.07),
  • Compass Therapeutics (CMPX +$0.02),

Flat (2)

  • Beam Therapeutics (BEAM)
  • Generation Bio (GBIO) – acquired

Wednesday’s Closing DOWN (10 of 26): 

  • Vertex (VRTX -$6.79 after Tuesday’s +$38.30 after Monday’s +$4.18),    
  • CRISPR Therapeutics (CRSP -$2.87),
  • Alnylam Pharmaceuticals (ALNY -$1.95 after Tuesday’s -$1.21 after Monday’s +$2.93),
  • Arrowhead Pharmaceuticals (ARWR -$1.10 after Tuesday’s -$1.47),
  • Ionis Pharmaceuticals (IONS -$0.87 after Tuesday’s +$0.30 after Monday’s +$1.32),
  • uniQure NV (QURE -$0.70 after Tuesday’s +$0.27 after Monday’s +$3.72),
  • Ultragenyx Pharmaceuticals (RARE -$0.63),
  • Vericel (VCEL -$0.52 after Tuesday’s -$0.72),
  • Regenxbio (RGNX -$0.52),
  • Solid Biosciences (SLDB -$0.47),

 

The Bottom Line: More of the … WHY

Enough of econs …

Now, investors will be watching for Friday's Personal Consumption Expenditures index (PCI) readings, still the feeling the effect of oil's dramatic recent surge on price pressures.

Let’s hope it comes in line with expectations

Worries about the knock-off effects from the Iran war have dominated markets this week, spurring volatility – ah da. Sort-term “it is” infects this week’s cycle!

As above, the Nasdaq eked out a gain, rising 0.08%, while the S&P 500 fell by the same amount while the Dow about 0.6%.

For the week: so far

  • The S&P 500 is up 35.78 points, or 0.5%.
  • The Dow is down 84.28 points, or 0.2%.
  • The Nasdaq is up 328.46 points, or 1.5%.
  • The Russell 2000 is up 17.59 points, or 0.7%.

 

Yet a usually forgotten thrill, “The US dollar index (DX-Y.NYB) is surging again — this time above the 99 level, which had contained it the prior 5 sessions.”

 

Earnings release dates: soon to be catching up

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Monday - 3/2 – Dyne Therapeutics (DYN)
  • Thursday – 3/5 – Regenxbio (RGNX), Compass therapeutics (CMPX)
  • Thursday – 3/12 – Capricor Therapeutics (CAPR)
  • Monday – 3/16 – Agenus (AGEN)
  • Wednesday – 3/25 – Precigen (PGEN)

 

RISK is always a factor remaining below the surface …  boiled-up with ... shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

March – 2nd week

  • 3/11 - Wednesday closed negative with 11 incliners, 26 decliners and 2 flats
  • 3/10 - Tuesday closed positive with 21 incliners, 16 decliners and 3 flats
  • 3/9 - Monday closed positive with 35 incliners, 2 decliners and 3 flats

March – 1st week

  • 3/6 - Friday closed negative with 14 incliners, 24 decliners and 2 flats
  • 3/5 – Thursday closed negative with 7 incliners, 32 decliners and 1 flat
  • 3 /4 – Wednesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 3/3 - Tuesday closed negative with 2 incliners, 36 decliners and 2 flats
  • 3/2 - Monday closed negative with 15 incliners, 23 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Wednesday: BioNTech (BNTX), AxoGen (AXGN) and Moderna (MRNA)
  • Tuesday: Vertex (VRTX), Capricor Therapeutics (CAPR) and Dyne Therapeutics (DYN)
  • Monday: Vertex (VRTX), IQIA Holdings (IQV) and UniQure NV (QURE)
  • Friday: UniQure NV (QURE), Capricor Therapeutics (CAPR) and Solid Biosciences (SLDB)

The worst three (3) in the session: Losers

  • Wednesday: Vertex (VRTX), CRISPR Therapeutics (CRSP) and Alnylam Pharmaceuticals (ALNY)
  • Tuesday: BioNTech (BNTX), CRISPR Therapeutics (CRSP) and IQIA Holdings (IQV)
  • Monday: Mesoblast (MESO) and Compass Therapeutics (CMPX)
  • Friday: Vertex (VRTX), IQIA Holdings (IQV) and Arrowhead Pharmaceuticals (ARWR)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.